Research programme: complement factor D inhibitors - Achillion Pharmaceuticals

Drug Profile

Research programme: complement factor D inhibitors - Achillion Pharmaceuticals

Alternative Names: ACH CFDIS

Latest Information Update: 07 Jan 2016

Price : $50

At a glance

  • Originator Achillion Pharmaceuticals
  • Class Anti-inflammatories; Small molecules
  • Mechanism of Action Complement factor D inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Age-related macular degeneration; Chronic obstructive pulmonary disease

Most Recent Events

  • 07 Jan 2016 Preclinical trials in Chronic obstructive pulmonary disease in USA (Inhalation) prior top January 2016 (Achillion pipeline, January 2016)
  • 15 Jul 2015 Preclinical trials in Age-related macular degeneration in USA (Intrvitreous)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top